METERED DOSE INHALER SUPPLIES BUSINESS PLAN
I. Executive Summary
Company Description
AeroCare Medical LLC—named to reflect airway support and clinical reliability—operates in the U.S. medical device sector, specializing in respiratory care. We manufacture and distribute metered dose inhalers and spacers from FDA-approved production lines staffed by biomedical engineers and quality experts. We sell direct-to-provider to remove distributor uncertainty and offer transparent pricing to hospitals, clinics, and group purchasing organizations. Launching in 2026, our first-year revenue target is $20,300,000. One line: reliable respiratory supplies, sold directly to clinicians.
Our core activities are regulated manufacturing, quality testing, direct sales, contract fulfillment, and provider training and support. What sets us apart is dedicated production capacity with inventory control that prevents shortages, clinical-grade design, and a provider-focused commercial model that shortens lead time and lowers total cost of ownership. Target markets are U.S. hospitals, large health systems, and outpatient pulmonary clinics. Short-term goal: hit the 2026 revenue target and achieve 98% on-time delivery; long-term goal: national supply partnerships and product line expansion. One line: dependable supply, clinical quality, and transparent pricing.
Problem
Millions of Americans with chronic respiratory conditions face inconsistent access to affordable metered dose inhalers (MDIs) and spacer devices, driven by supply chain vulnerabilities, retail shortages, and high out-of-pocket costs. Unreliable supply and high cost put patients at risk of severe exacerbations.
Healthcare providers increasingly work with distributors that lack respiratory-specific forecasting, stocking, and patient-support capabilities, producing treatment interruptions, higher emergency care use, and added system costs. Current distribution and supply models fail to guarantee continuous, affordable access to maintenance respiratory therapy.
Solution
Millions of Americans with chronic respiratory conditions face stockouts, price volatility, and unreliable sourcing for inhalers and spacers. We solve this by vertically integrating specialized manufacturing, sterilization, and direct-to-provider distribution for precision inhalation devices, ensuring steady supply and predictable pricing for hospitals and clinics.
Product lines include rescue, steroid, and combo inhalers, valved and pediatric spacers, plus manufacturing and sterilization services; Year 1 EBITDA: $14,965,000.
Mission Statement
We empower better management of chronic respiratory diseases by ensuring every patient has reliable access to essential medication delivery tools. We commit to supply chain transparency, manufacturing excellence, and equipping healthcare providers with practical tools to improve patient outcomes while serving the U.S. healthcare system. Our goal is to be the most trusted name in respiratory medical supplies and to achieve $127,700,000 in revenue by 2030.
Key Success Factors
Our success rests on focused product strategy, regulatory compliance, sales channels, manufacturing efficiency, and rapid breakeven.
-
Specialized focus on respiratory devices driving product-market fit.
-
High-volume GPO contracts securing predictable, large-scale demand.
-
1.5% of revenue allocated to testing ensuring 100% FDA compliance.
-
Direct sales team and B2B portal delivering superior customer experience vs. general distributors.
-
Automated manufacturing and assembly supporting high margins and a 283.45% ROE; breakeven in month one.
Financial Summary
Financial snapshot: rapid revenue and EBITDA growth with near-term breakeven and minimal cash runway requirements.
Ratio | 2026 | 2027 | 2028 |
Projected Revenue | $20,300,000 | $37,345,000 | $60,520,000 |
Projected EBITDA | $14,965,000 | $28,718,000 | $47,624,000 |
Expected ROI | 283.45% (ROE) | | |
Financial requirements: 2026 CapEx of $1,560,000; minimum cash required $1,235,000 (Jan-26). Payback and breakeven occur in one month.
Outlook: strong profitability and liquidity support rapid scale from 2026 to 2030.
Funding Requirements
We need $2,795,000 to launch in Jan-2026 and achieve one-month payback and breakeven timelines.
Categories | Amount, USD |
Medical-grade injection molds | $250,000 |
Cleanroom construction | $300,000 |
Assembly line automation | $450,000 |
Laboratory testing equipment | $120,000 |
Sterilization chamber | $180,000 |
ERP system implementation | $65,000 |
Office and warehouse furniture & distribution fleet | $195,000 |
Capex subtotal | $1,560,000 |
Working capital | $1,235,000 |
Total funding required | $2,795,000 |
Projected revenue rises from $20,300,000 in 2026 to $127,700,000 by 2030, with EBITDA growing from $14,965,000 to $102,843,000 over the same period.